Recruiting Ovarian Cancer Studies in Mobile
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensiti...
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active...
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Canc...
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back ...
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression....
About Ovarian Cancer Clinical Trials in Mobile
Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.
There are currently 5 ovarian cancer clinical trials recruiting participants in Mobile, ALABAMA. These studies are seeking a combined 1,201 participants. Research is being sponsored by AbbVie, Genelux Corporation, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ovarian Cancer Clinical Trials in Mobile — FAQ
Are there ovarian cancer clinical trials in Mobile?
Yes, there are 5 ovarian cancer clinical trials currently recruiting in Mobile, ALABAMA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Mobile?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Mobile research site will contact you about next steps.
Are clinical trials in Mobile free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Mobile studies also compensate for your time and travel.
What ovarian cancer treatments are being tested?
The 5 active trials in Mobile are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.
Data updated March 2, 2026 from ClinicalTrials.gov